Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + epirubicin + cyclophosphamide + TE + iodine
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This is a combination chemotherapy regimen containing five agents: - **Fluorouracil** (5-FU): A pyrimidine analog antimetabolite that inhibits thymidylate synthase, interfering with DNA synthesis and cell division. - **Epirubicin**: An anthracycline antibiotic that intercalates into DNA and inhibits topoisomerase II, leading to DNA strand breaks and apoptosis. - **Cyclophosphamide**: An alkylating agent that crosslinks DNA strands, preventing cell replication. - **TE** (likely refers to docetaxel [T] plus epirubicin [E], but this abbreviation is ambiguous; see comments). - **Iodine** (unclear in this context; possibly refers to radioiodine or an imaging/therapeutic adjunct). The FEC regimen (fluorouracil, epirubicin, cyclophosphamide) is well-established for the treatment of breast cancer[1][2][3]. The addition of "TE" and "iodine" suggests a modified or experimental protocol. Each component has distinct mechanisms targeting rapidly dividing cancer cells. This combination would be considered investigational unless further clarified.
- Other names
- FEC-TEI
02
Targets
TOP2A (DNA topoisomerase II)MicrotubuleDNATS (Thymidylate synthase)
Beyond the preview
Go deeper on fluorouracil + epirubicin + cyclophosphamide + TE + iodine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + epirubicin + cyclophosphamide + TE + iodine.